An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
Stopped early · Phase 2
Conditions studied: Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related PTLD, EBV-Related Lymphoproliferative Disorder
In brief
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
Key facts
- Study ID
- NCT05011058
- Run by
- Viracta Therapeutics, Inc.
- People needed
- 102
- Starts
- 2021-05-28
- Expected to finish
- 2025-01-31
- Last updated by the study team
- 2025-07-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- David Geffen School of Medicine - UCLA — Los Angeles, California, United States
- University of California Irvine — Orange, California, United States
- Scripps MD Anderson Cancer Center — San Diego, California, United States
- UCSF Hematology and Blood and Marrow Transplant — San Francisco, California, United States
- University of Colorado Cancer Center — Aurora, Colorado, United States
- University of Maryland Medical Center — Baltimore, Maryland, United States
- John Theurer Cancer Center: Hackensack Univeristy — Hackensack, New Jersey, United States
- Icahn School of Medicine at Mount Sinai — New York, New York, United States
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
- Ohio State University: Wexner Medical Center — Columbus, Ohio, United States
- Sidney Kimmel Cancer Center - Jefferson Health — Philadelphia, Pennsylvania, United States
- Medical University of South Carolina — Charleston, South Carolina, United States
- Harold C. Simmons Comprehensive Cancer Center — Dallas, Texas, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- University of Utah, Huntsman Cancer Institute — Salt Lake City, Utah, United States
- Box Hill Hospital — Melbourne, Victoria, Australia
- The Alfred Hospital — Melbourne, Victoria, Australia
- CEPEVILLE - Instituto Joinvilense de Hematologia e Oncologia — Joinville, Brazil
- Ruschel Medicina e Pesquisa Clinica — Rio de Janeiro, Brazil
- CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia — Santo André, Brazil
- CIPE Centro Internacional de Pesquisa - AC Camargo Cancer Center — São Paulo, Brazil
- HCFMUSP - Hospital das Clínicas da Faculdade de Medicina Universidade de São Paulo — São Paulo, Brazil
- Cross Cancer Institute — Edmonton, Alberta, Canada
- The University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.